Adage Capital Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-148,972
| Closed | -$27.4M | – | 970 |
|
|
2025
Q4 | $27.4M | Sell |
148,972
-187,500
| -56% | -$32.9M | 0.04% | 398 |
|
|
2025
Q3 | $51.6M | Buy |
336,472
+173,776
| +107% | +$26.3M | 0.08% | 235 |
|
|
2025
Q2 | $22.7M | Sell |
162,696
-160,940
| -50% | -$22.6M | 0.04% | 416 |
|
|
2025
Q1 | $47.6M | Buy |
323,636
+146,917
| +83% | +$21.3M | 0.09% | 235 |
|
|
2024
Q4 | $23.2M | Buy |
+176,719
| New | +$24.7M | 0.04% | 406 |
|
|
2024
Q3 | – | Sell |
-173,234
| Closed | -$27M | – | 877 |
|
|
2024
Q2 | $27M | Buy |
+173,234
| New | +$26.1M | 0.05% | 362 |
|
|
2023
Q4 | – | Sell |
-719,965
| Closed | -$97.5M | – | 857 |
|
|
2023
Q3 | $97.5M | Buy |
719,965
+213,411
| +42% | +$29.1M | 0.22% | 111 |
|
|
2023
Q2 | $72.5M | Buy |
506,554
+356,554
| +238% | +$52.5M | 0.16% | 148 |
|
|
2023
Q1 | $20.8M | Sell |
150,000
-488,363
| -77% | -$65.7M | 0.05% | 403 |
|
|
2022
Q4 | $86.6M | Buy |
638,363
+401,011
| +169% | +$50.3M | 0.21% | 119 |
|
|
2022
Q3 | $26M | Sell |
237,352
-23,628
| -9% | -$3M | 0.06% | 337 |
|
|
2022
Q2 | $34.5M | Sell |
260,980
-94,020
| -26% | -$12.3M | 0.08% | 269 |
|
|
2022
Q1 | $47.1M | Sell |
355,000
-20,000
| -5% | -$2.4M | 0.09% | 228 |
|
|
2021
Q4 | $43.7M | Sell |
375,000
-1,031,832
| -73% | -$121M | 0.08% | 257 |
|
|
2021
Q3 | $169M | Buy |
+1,406,832
| New | +$164M | 0.33% | 59 |
|
|
2020
Q4 | – | Sell |
-337,500
| Closed | -$37M | – | 811 |
|
|
2020
Q3 | $37M | Buy |
337,500
+250,000
| +286% | +$27.8M | 0.09% | 229 |
|
|
2020
Q2 | $9.26M | Sell |
87,500
-187,500
| -68% | -$19.4M | 0.02% | 536 |
|
|
2020
Q1 | $24.6M | Buy |
275,000
+75,000
| +38% | +$7.06M | 0.07% | 280 |
|
|
2019
Q4 | $19.9M | Sell |
200,000
-50,000
| -20% | -$4.71M | 0.05% | 388 |
|
|
2019
Q3 | $22.3M | Buy |
+250,000
| New | +$21.7M | 0.05% | 342 |
|
|
2019
Q1 | – | Sell |
-250,000
| Closed | -$19M | – | 696 |
|
|
2018
Q4 | $19M | Hold |
250,000
| – | – | 0.05% | 347 |
|
|
2018
Q3 | $19.8M | Sell |
250,000
-425,000
| -63% | -$32.1M | 0.04% | 404 |
|
|
2018
Q2 | $47.4M | Sell |
675,000
-300,000
| -31% | -$21.6M | 0.11% | 232 |
|
|
2018
Q1 | $68.2M | Sell |
975,000
-75,000
| -7% | -$5.2M | 0.16% | 168 |
|
|
2017
Q4 | $72.9M | Buy |
1,050,000
+325,000
| +45% | +$21.9M | 0.16% | 150 |
|
|
2017
Q3 | $49.1M | Buy |
+725,000
| New | +$45.8M | 0.12% | 224 |
|
|
2017
Q2 | – | Sell |
-50,000
| Closed | -$3.11M | – | 705 |
|
|
2017
Q1 | $3.11M | Sell |
50,000
-244,366
| -83% | -$14.2M | 0.01% | 643 |
|
|
2016
Q4 | $16.1M | Sell |
294,366
-5,634
| -2% | -$320K | 0.04% | 420 |
|
|
2016
Q3 | $19.7M | Buy |
+300,000
| New | +$19.6M | 0.05% | 387 |
|
|
2016
Q1 | – | Sell |
-10,000
| Closed | -$679K | – | 688 |
|
|
2015
Q4 | $679K | Buy |
+10,000
| New | +$656K | ﹤0.01% | 669 |
|
|
2013
Q4 | – | Sell |
-400,000
| Closed | -$20.8M | – | 684 |
|
|
2013
Q3 | $20.8M | Buy |
+400,000
| New | +$20.1M | 0.06% | 366 |
|
Other funds holding AZN
IA
VCM
VAM
Adage Capital Partners's AZN Position: Q1 2026 in Review
Adage Capital Partners sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 148,972 shares — an estimated $27.4M sold.
Adage Capital Partners first reported a position in AZN in Q3 2013 and held it in 31 quarters. The position peaked at $169M in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Adage Capital Partners reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- Adage Capital Partners sold 148,972 AstraZeneca shares in Q1 2026, an estimated $27.4M.
- Adage Capital Partners first reported a position in AstraZeneca in Q3 2013 and held it in 31 quarters.
- Adage Capital Partners's AstraZeneca position peaked at $169M in Q3 2021.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.